Home > Boards > US Listed > Biotechs > Blueprint Medicines Corporation (BPMC)

Blueprint Medicines Corp.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
TFMG Member Profile
Member Level 
Followed By 55
Posts 2,228
Boards Moderated 4
Alias Born 04/28/19
160x600 placeholder
JMP Securities Thinks Blueprint Medicines’ Stock is Going to Recover TipRanks - 1/12/2022 1:40:36 PM
Blueprint Medicines expects FY21 revenue at high end of $170M-$180M guidance range Seeking Alpha - 1/10/2022 2:16:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/10/2022 8:28:30 AM
Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy Leadership PR Newswire (US) - 1/10/2022 8:00:00 AM
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire (US) - 1/6/2022 4:01:00 PM
JMP Securities Keeps Their Buy Rating on Blueprint Medicines (BPMC) TipRanks - 1/6/2022 12:15:42 AM
Blueprint Medicines names new CEO in leadership shakeup Seeking Alpha - 1/5/2022 8:40:26 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/5/2022 8:08:51 AM
Blueprint Medicines Announces CEO and Leadership Transition Plan PR Newswire (US) - 1/5/2022 8:00:00 AM
Blueprint Medicines completes acquisition of Lengo Therapeutics Seeking Alpha - 12/30/2021 9:16:43 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/30/2021 9:12:03 AM
Blueprint Medicines Completes Acquisition of Lengo Therapeutics PR Newswire (US) - 12/30/2021 8:51:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/23/2021 5:10:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/17/2021 4:03:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/15/2021 4:24:26 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/10/2021 4:26:35 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 12/10/2021 4:25:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/9/2021 4:03:19 PM
Blueprint Medicines Appoints Daniella Beckman to its Board of Directors PR Newswire (US) - 12/9/2021 4:01:00 PM
Blueprint Medicines grants non-qualified stock options to 13 new employees Seeking Alpha - 12/7/2021 4:08:25 PM
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire (US) - 12/7/2021 4:01:00 PM
Nature Medicine Publishes Results from Two Registration Studies of AYVAKIT® (avapritinib) Showing Sustained Benefits in Patients with Advanced Systemic Mastocytosis PR Newswire (US) - 12/6/2021 4:01:00 PM
Blueprint Medicines to acquire precision oncology company Lengo Therapeutics Seeking Alpha - 11/29/2021 8:00:26 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/29/2021 7:05:15 AM
Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics PR Newswire (US) - 11/29/2021 7:00:00 AM
TFMG Member Level  Sunday, 06/21/20 02:15:20 PM
Re: None
Post # of 16 
Blueprint Medicines Corp.


Blueprint Medicines Corp . is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.




Official InvestorsHub (IHUB) Profile for #TFMG | #theFinancialMarketingGroup:

#BullishCharts - https://investorshub.advfn.com/BullishChartscom-38003/

#TopMarketGainers - https://investorshub.advfn.com/Chart-Analysis-TopMarketGainerscom-36847/
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences